Literature DB >> 32890594

Liver biopsy reliability in clinical trials: Thoughts from a liver pathologist.

Elizabeth Matthews Brunt1.   

Abstract

Keywords:  Liver biopsy; NASH; Pathology reliability

Year:  2020        PMID： 32890594     DOI： 10.1016/j.jhep.2020.08.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  3 in total

1.  Current considerations for clinical management and care of non-alcoholic fatty liver disease: Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH).

Authors:  Giada Sebastiani; Keyur Patel; Vlad Ratziu; Jordan J Feld; Brent A Neuschwander-Tetri; Massimo Pinzani; Salvatore Petta; Annalisa Berzigotti; Peter Metrakos; Naglaa Shoukry; Elizabeth M Brunt; An Tang; Jeremy F Cobbold; Jean-Marie Ekoe; Karen Seto; Peter Ghali; Stéphanie Chevalier; Quentin M Anstee; Heather Watson; Harpreet Bajaj; James Stone; Mark G Swain; Alnoor Ramji
Journal:  Can Liver J       Date:  2022-02-04

2.  Metabolomic Profiling for Histologically Fibrotic Stage in Chronic Drug-Induced Liver Injury.

Authors:  Xian He; Ming-Xi Zhou; Cheng Cheng; Shan-Shan Li; Yuan Gao; Zhi-Tao Ma; Xin-Hua Song; Zhao-Fang Bai; Zheng-Sheng Zou; Xiao-He Xiao; Jia-Bo Wang; Ya-Wen Lu
Journal:  Front Pharmacol       Date:  2022-05-20       Impact factor: 5.988

3.  Improved pathology reporting in NAFLD/NASH for clinical trials.

Authors:  Caitlin Rose Langford; Marc H Goldinger; Darren Treanor; Clare McGenity; Jonathan R Dillman; Daniela S Allende; Robert Goldin; Elizabeth M Brunt; Kurt Zatloukal; Helmut Denk; Kenneth A Fleming
Journal:  J Clin Pathol       Date:  2021-11-09       Impact factor: 3.411
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.